Saturday, September 23, 2023
Saturday, September 23, 2023

Professor Andrew Holden Joins the VESTECK Scientific Advisory Board

Professor Andrew Holden is currently the Director of Northern Region Interventional Radiology Service and is based at Auckland City Hospital.  As well, he is Professor of Radiology at the University of Auckland and Co-Director of the Auckland Endovascular Service.

Professor Andrew Holden is known worldwide as an educator, clinician and the author of over 100 peer-reviewed articles.  He has been involved in over 75 medical device trials and is a frequent Principal Investigator, personally performing many “first in human” procedures.

“The VESTECK SUTURE-TIGHT catheter appears to be very straightforward, the right technology at the right time,” said Dr. Holden. “Around the world, approximately 80% of all Aortic Abdominal Aneurysm patients needing repairs, receive an endovascular repair (EVAR).  The “SUTURE-TIGHT”TM catheter, fixes the EVAR graft to the aorta. This should significantly reduce the number of patients returning for complex repair procedures and eliminate their associated procedural costs.”

In 2018 Dr. Holden was recognized for his contributions to vascular and endovascular intervention, being awarded an Officer of the New Zealand Order of Merit medal.

We are humbled that Dr. Holden thinks so highly of the VESTECK technology and team to join the Scientific Advisory Board, commented VESTECK CEO Joe Rafferty.  “Professor Holden is respected around the world as a skilled interventionalist and critical thinker. He will absolutely challenge us to bring the finest technology for physicians and patients.”

The VESTECK “SUTURE-TIGHT” catheter secures endovascular aortic repair grafts to the aorta at the time of initial implant or during repair procedures. VESTECK is in preparation for a 100-patient clinical trial.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

MORE EXECUTIVES

Carthera Appoints Dr Oern Stuge as Chairman of Board of Directors

Dr Oern Stuge brings 30+ years expertise with a wealth of experience in product development and commercial launches to support Carthera’s future growth.

Cytomos Appoints a New Director as £4 Mill Investment Sets Path for Commercialisation of Groundbreaking Cell Analysis Technology

The biotech company’s appointment of industry leader Dr Sharon Brownlow as Non-Executive Director further enhances Cytomos’ senior management team and its unique value proposition to key industry markets.

Kindeva Drug Delivery Appoints Brian Schubmehl as Chief Human Resources Officer

Brian Schubmehl brings more than two decades of diverse and senior global leadership expertise that has spanned private equity, startup, and publicly traded organizations.

Joseph Schwab MD, MS, to Lead Spine-Oncology Program and Center for Surgical Technology and AI Research at Cedars-Sinai

Joseph Schwab combines extensive experience in translational research and clinical trials with a record of high-quality clinical care. He specializes in the management of benign and malignant bone tumors as well as spinal disorders, including stenoses and myelopathy. His expertise will drive transformative advancements in spine oncology and surgical technology at Cedars-Sinai.

Perimeter Medical Imaging AI Strengthens Leadership Team with Appointment of Experienced MedTech Executive, Adam Hodges, as Vice President, Sales and Marketing

Adam Hodges brings more than 20 years of commercialization experience in the medical device industry. Most recently, Adam was Vice President of Sales at SIA Health, leading the commercial acceleration of DuraSorb®, which was acquired by Integra LifeSciences (NASDAQ: IART) in December 2022. During his tenure at SIA, Adam grew sales revenue by more than 5X in less than two years and previously served concurrent roles of Vice President of Strategic Accounts and Regional Business Director.

By using this website you agree to accept Medical Device News Magazine Privacy Policy